TY - JOUR
T1 - Health-Related Quality of Life in Testicular Cancer Survivors in Japan
T2 - A Multi-Institutional, Cross-Sectional Study Using the EORTC QLQ-TC26
AU - Yamashita, Shinichi
AU - Kakimoto, Kenichi
AU - Uemura, Motohide
AU - Kishida, Takeshi
AU - Kawai, Koji
AU - Nakamura, Terukazu
AU - Goto, Takayuki
AU - Osawa, Takahiro
AU - Yamada, Shigeyuki
AU - Nishimura, Kazuo
AU - Nonomura, Norio
AU - Nishiyama, Hiroyuki
AU - Shiraishi, Takumi
AU - Ukimura, Osamu
AU - Ogawa, Osamu
AU - Shinohara, Nobuo
AU - Suzukamo, Yoshimi
AU - Ito, Akihiro
AU - Arai, Yoichi
N1 - Funding Information:
Funding Support: This work was supported in part by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science ( 18K09185 ).
Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2021/10
Y1 - 2021/10
N2 - Objective: To evaluate the health-related quality of life (QOL) of testicular cancer (TC) survivors using the Japanese version of the EORTC QLQ-TC26 questionnaire in a multi-institutional, cross-sectional study. Methods: This study recruited TC survivors who were followed after treatment for TC at eight high-volume institutions between January, 2018 and March, 2019. The participants completed the EORTC QLQ-TC26 questionnaire and mailed the completed questionnaires to a central institution. The QOL scores were assessed according to therapeutic modality (watchful waiting, WW; chemotherapy, CT; and CT followed by retroperitoneal lymph node dissection, CT+RPLND) and follow-up period and compared using analysis of variance and Student's t-test. Results: A total of 567 TC survivors responded to the questionnaire. The median age at response was 43 years (IQR 35-51 years), and the median follow-up was 5.2 years (IQR 2.2-10.0 years). As for treatment side effects and physical limitations, the scores of the CT+RPLND group were significantly higher than those of the WW group, especially within one year after treatment. In addition, TC survivors in the CT+RPLND group reported high impairment related to job and education problems and future perspective less than 5 years after treatment. Even TC survivors in the WW group were anxious about job and education issues within one year after treatment. Conclusion: TC survivors were anxious about not only cancer recurrence, but also their jobs and education. TC patients should be given appropriate information on QOL after treatment for TC to attenuate post-treatment anxiety and improve their health-related QOL.
AB - Objective: To evaluate the health-related quality of life (QOL) of testicular cancer (TC) survivors using the Japanese version of the EORTC QLQ-TC26 questionnaire in a multi-institutional, cross-sectional study. Methods: This study recruited TC survivors who were followed after treatment for TC at eight high-volume institutions between January, 2018 and March, 2019. The participants completed the EORTC QLQ-TC26 questionnaire and mailed the completed questionnaires to a central institution. The QOL scores were assessed according to therapeutic modality (watchful waiting, WW; chemotherapy, CT; and CT followed by retroperitoneal lymph node dissection, CT+RPLND) and follow-up period and compared using analysis of variance and Student's t-test. Results: A total of 567 TC survivors responded to the questionnaire. The median age at response was 43 years (IQR 35-51 years), and the median follow-up was 5.2 years (IQR 2.2-10.0 years). As for treatment side effects and physical limitations, the scores of the CT+RPLND group were significantly higher than those of the WW group, especially within one year after treatment. In addition, TC survivors in the CT+RPLND group reported high impairment related to job and education problems and future perspective less than 5 years after treatment. Even TC survivors in the WW group were anxious about job and education issues within one year after treatment. Conclusion: TC survivors were anxious about not only cancer recurrence, but also their jobs and education. TC patients should be given appropriate information on QOL after treatment for TC to attenuate post-treatment anxiety and improve their health-related QOL.
UR - http://www.scopus.com/inward/record.url?scp=85105278531&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105278531&partnerID=8YFLogxK
U2 - 10.1016/j.urology.2021.02.039
DO - 10.1016/j.urology.2021.02.039
M3 - Article
C2 - 33785401
AN - SCOPUS:85105278531
SN - 0090-4295
VL - 156
SP - 173
EP - 180
JO - Urology
JF - Urology
ER -